Multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species

被引:57
作者
Morace, G
Amato, G
Bistoni, F
Fadda, G
Marone, P
Montagna, MT
Oliveri, S
Polonelli, L
Rigoli, R
Mancuso, I
La Face, S
Masucci, L
Romano, L
Napoli, C
Tatò, D
Buscema, MG
Belli, CMC
Piccirillo, MM
Conti, S
Covan, S
Fanti, F
Cavanna, C
D'Alò, F
Pitzurra, L
机构
[1] Univ Milan, Ist Microbiol, I-20133 Milan, Italy
[2] Azienda Osped Rilievo Nazl, Lab Patol Clin, Naples, Italy
[3] Univ Perugia, Sez Microbiol, Dipartimento Med Sperimentale & Sci Biochim, I-06100 Perugia, Italy
[4] Univ Cattolica Sacro Cuore, Ist Microbiol, Rome, Italy
[5] Ist Ricovero & Cura Carattere Sci, Lab Batteriol & Micol, Pavia, Italy
[6] Univ Bari, Sez Igiene, Dipartimento Med Interna & Med Pubbl, Bari, Italy
[7] Univ Catania, Sez Microbiol, Dipartimento Sci Microbiol & Sci Ginecol, Catania, Italy
[8] Univ Parma, Sez Microbiol, Dipartimento Patol & Med Lab, I-43100 Parma, Italy
[9] Osped Ca Foncello, Microbiol Lab, Treviso, Italy
[10] Pfizer Italia SpA, Rome, Italy
关键词
D O I
10.1128/JCM.40.8.2953-2958.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Fluconazole susceptibility among 800 clinical Candida isolates (60% C albicans) and two control strains (C krusei ATCC 6258 and C. parapsilosis ATCC 22019) was tested with the NCCLS M27-A method (gold standard) and six commercial products (Candifast, disk Etest, Fungitest, Integral System Yeasts, and Sensititre YeastOne). Results were classified as susceptible, susceptible-dose dependent, or resistant using M27-A breakpoints or, for Fungitest, Integral System Yeasts, and Candifast, as susceptible, intermediate, or resistant, according to the manufacturers' instructions. Concordance with NCCLS M27-A results was analyzed with the chi(2) test. Intra- and interlaboratory reproducibility was also evaluated. NCCLS M27-A (90.1%), Etest (93.1%), Sensititre YeastOne (93.1%), disk (96.7%), Fungitest (92.6%), Integral System Yeasts (40.6%), and Candifast (6.0%) classified the indicated percentages of C. albicans isolates as susceptible. Among non-C albicans strains, the percentages of susceptible isolates were as follows: NCCLS M27-A, 74.0%; Etest, 83.8%; Sensititre YeastOne, 64.1%; disk, 60.6%; Fungitest, 76.6%; Integral System Yeasts, 28.3%; and Candifast, 27.4%. All methods except Candifast and Integral System Yeasts showed good agreement with NCCLS M27-A results for both C albicans and non-C. albicans isolates. Intralaboratory reproducibility was excellent for NCCLS M27-A, Etest, Sensititre YeastOne, disk, and Fungitest (88 to 91%). Similar results emerged from the interlaboratory reproducibility evaluation. Our findings indicate that some commercial methods can be useful for fluconazole susceptibility testing of clinical Candida isolates. Those characterized by a lack of medium standardization and/or objective interpretative criteria should be avoided. Particular caution is necessary when testing is being done for clinical and epidemiological purposes.
引用
收藏
页码:2953 / 2958
页数:6
相关论文
共 18 条
  • [1] Arthington-Skaggs BA, 2000, J CLIN MICROBIOL, V38, P2254
  • [2] Quality control limits for broth microdilution susceptibility tests of ten antifungal agents
    Barry, AL
    Pfaller, MA
    Brown, SD
    Espinel-Ingroff, A
    Ghannoum, MA
    Knapp, C
    Rennie, RP
    Rex, JH
    Rinaldi, MG
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) : 3457 - 3459
  • [3] Cormican MG, 1996, J ANTIMICROB CHEMOTH, V38, P561
  • [4] Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans
    Davey, KG
    Holmes, AD
    Johnson, EM
    Szekely, A
    Warnock, DW
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (04) : 926 - 930
  • [5] Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Clyptococcus neoformans
    Davey, KG
    Szekely, A
    Johnson, EM
    Warnock, DW
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) : 439 - 444
  • [6] MERS J, 2000, DIAGN MICROBIOL INFE, V36, P213
  • [7] National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L
  • [8] Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients
    Perea, S
    López-Ribot, JL
    Kirkpatrick, WR
    McAtee, RK
    Santillán, RA
    Martínez, M
    Calabrese, D
    Sanglard, D
    Patterson, TF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) : 2676 - 2684
  • [9] Multisite reproducibility of MIC results by the Sensititre® YeastOne colorimetric antifungal susceptibility panel
    Pfaller, MA
    Messer, SA
    Hollis, RJ
    Espinel-Ingroff, A
    Ghannoum, MA
    Plavan, H
    Killian, SB
    Knapp, CC
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 31 (04) : 543 - 547
  • [10] Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media
    Pfaller, MA
    Messer, SA
    Karlsson, Å
    Bolmström, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (09) : 2586 - 2589